Ovarian Cancer Clinical Trials in San Antonio

Showing 81-95 of 95 trials

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

NCT00880360

This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.

Epithelial Ovarian CancerExtraovarian Peritoneal CancerFallopian Tube Carcinoma

The University of Texas Health Science Center at San Antonio19 participantsStarted Feb 2007

San Antonio, Texas, United States

TERMINATEDPHASE3< 1 mile

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

NCT01281254

To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS) The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

Amgen223 participantsStarted Apr 2011

Los Angeles, California, United States • San Francisco, California, United States • Norwalk, Connecticut, United States +103 more locations

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Ovarian Cancer Trials in Other Cities

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

Clinical Trial for Ovarian Cancer (OvaRex®)

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Ovarian Cancer Vaccine for Patients in Remission

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Other Conditions in San Antonio